Nuveen Asset Management, LLC Oncorus, Inc. Transaction History

Nuveen Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.86 $100,056 - $178,946	-96,208 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.44 - $5.62 $4,258 - $16,618	2,957 Added 3.17%	96,208 $159,000
Q4 2021 Feb 14, 2022	SELL	$5.03 - $11.63 $125,976 - $291,273	-25,045 Reduced 21.17%	93,251 $455,000
Q3 2021 Nov 12, 2021	BUY	$9.29 - $14.27 $8,017 - $12,315	863 Added 0.73%	118,296 $1.14 Million
Q2 2021 Aug 16, 2021	BUY	$13.3 - $17.3 $1.27 Million - $1.65 Million	95,508 Added 435.61%	117,433 $1.62 Million
Q1 2021 May 17, 2021	BUY	$11.89 - $35.55 $131,527 - $393,254	11,062 Added 101.83%	21,925 $305,000
Q4 2020 Feb 16, 2021	BUY	$15.0 - $35.15 $162,945 - $381,834	10,863 New	10,863 $351,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.